NasdaqGS:REGNBiotechs
Regeneron Data On EYLEA HD Dosing Shapes Retinal Disease Outlook
Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting final long term Phase 3 data from its QUASAR and ELARA trials for EYLEA HD at a major ophthalmology conference.
The data cover serious retinal conditions, including macular edema following retinal vein occlusion and wet age related macular degeneration.
New evidence supports expanded dosing options, including less frequent dosing for some patients and monthly dosing for others.
The presentations focus on both efficacy and safety...